loading...| Preferred Name |
altretamine |
|
| Synonyms |
Hexaloids 2,4,6-tris(dimethylamino)-s-triazine N,N,N',N',N",N"-hexamethyl-1,3,5-triazine-2,4,6-triamine hexamethylmelamine Hemel RB-1515 HMM ENT-50852 HXM Hexalen Hexastat WR-95704 Hexinawas |
|
| Definitions |
A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity. Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C544" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C544" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039475 |
|
| altLabel |
Hexaloids 2,4,6-tris(dimethylamino)-s-triazine N,N,N',N',N",N"-hexamethyl-1,3,5-triazine-2,4,6-triamine hexamethylmelamine Hemel RB-1515 HMM ENT-50852 HXM Hexalen Hexastat WR-95704 Hexinawas |
|
| CAS Registry |
645-05-6 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000039705 http://purl.bioontology.org/ontology/PDQ/CDR0000039321 http://purl.bioontology.org/ontology/PDQ/CDR0000039517 http://purl.bioontology.org/ontology/PDQ/CDR0000041466 http://purl.bioontology.org/ontology/PDQ/CDR0000039690 http://purl.bioontology.org/ontology/PDQ/CDR0000041001 http://purl.bioontology.org/ontology/PDQ/CDR0000041283 http://purl.bioontology.org/ontology/PDQ/CDR0000040929 http://purl.bioontology.org/ontology/PDQ/CDR0000039699 http://purl.bioontology.org/ontology/PDQ/CDR0000039313 http://purl.bioontology.org/ontology/PDQ/CDR0000039708 http://purl.bioontology.org/ontology/PDQ/CDR0000039704 http://purl.bioontology.org/ontology/PDQ/CDR0000041000 http://purl.bioontology.org/ontology/PDQ/CDR0000039518 http://purl.bioontology.org/ontology/PDQ/CDR0000039684 http://purl.bioontology.org/ontology/PDQ/CDR0000040296 http://purl.bioontology.org/ontology/PDQ/CDR0000039319 http://purl.bioontology.org/ontology/PDQ/CDR0000039314 http://purl.bioontology.org/ontology/PDQ/CDR0000040984 http://purl.bioontology.org/ontology/PDQ/CDR0000039622 http://purl.bioontology.org/ontology/PDQ/CDR0000039697 http://purl.bioontology.org/ontology/PDQ/CDR0000039640 http://purl.bioontology.org/ontology/PDQ/CDR0000041707 http://purl.bioontology.org/ontology/PDQ/CDR0000042100 http://purl.bioontology.org/ontology/PDQ/CDR0000039706 http://purl.bioontology.org/ontology/PDQ/CDR0000039691 |
|
| cui |
C1448360 C0019453 C1448359 C1522394 C0594753 C0733617 C1522393 |
|
| Date last modified |
2006-12-14 |
|
| definition |
A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity. Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C544" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C544" NCI Thesaurus) |
|
| IND Code |
954 |
|
| Legacy PDQ ID |
2109 |
|
| LT |
TRD |
|
| NCI ID |
C544 |
|
| notation |
CDR0000039475 |
|
| NSC Code |
13875 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
altretamine |
|
| tui |
T109 T131 T121 |